Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27347394
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27347394
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 F1000Res
2016 ; 5
(ä): ä Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Recent advances in primary Sjogren s syndrome
#MMPMID27347394
Holdgate N
; St Clair EW
F1000Res
2016[]; 5
(ä): ä PMID27347394
show ga
Primary Sjögren's syndrome, a chronic inflammatory process, is among the most
commonly occurring rheumatologic diseases. The clinical hallmark of this disease
is exocrine gland dysfunction, resulting predominately in dry eyes and dry mouth.
However, the disease often extends beyond the exocrine glands to seriously affect
other organs systems, such as the lungs, kidneys, and nervous system. Moreover,
patients with primary Sjögren's syndrome develop non-Hodgkin's B cell lymphoma at
a substantially higher rate than the general population. New research has
improved our understanding of disease mechanisms, with notable advances in our
knowledge about the genetic susceptibility of disease, the molecular details of
the chronic inflammatory response in the salivary glands, and the complex role of
the type 1 interferon pathway. The pipeline of drugs under development for the
treatment of primary Sjögren's syndrome is enriched with novel biologics and
small molecular entities targeting the pathogenic process. Herein, we summarize
the latest advances in elucidating the pathogenesis of primary Sjögren's syndrome
and highlight new drugs in clinical development aiming to reverse the glandular
dysfunction and favorably impact the systemic features of this disease.
free
free
free
